NCT04887870

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: Mirati Therapeutics Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies

Detailed description

Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that inhibits several closely related RTKs including the TAM family (Tyro3/Axl/MERTK), VEGFR2, KIT, and MET. The current study is designed to allow continued access to sitravatinib and to evaluate the safety and tolerability of sitravatinib alone or in combination with other anticancer therapies in patients who are deriving clinical benefit in a previous parent clinical trial.

Conditions

• Advanced or Metastatic Solid Malignancies

Interventions

Type	Name	Description
DRUG	Sitravatinib	Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
DRUG	Nivolumab	Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
DRUG	Pembrolizumab	Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
DRUG	Enfortumab Vedotin-Ejfv	Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
DRUG	Ipilimumab	Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody

Timeline

• Start date: 2021-06-29
• Primary completion: 2025-04-21
• Completion: 2025-09-25
• First posted: 2021-05-14
• Last updated: 2025-10-10

Locations

13 sites across 1 country: United States

Regulatory

• FDA-regulated drug study